SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT2) inhibitors suppress the decline in estimated glomerular filtration rate (eGFR), even in patients with type 2 diabetes and renal impairment (1), (2).